Jul 29, 2025 | biologics, Biosimilars, Cost Savings, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug advertising, Drug costs, Health care costs, High-value formulary, MedBen Rx, Pharmacy, Rx Costs, Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Jun 16, 2025 | Drug costs, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs
A recent Statista article examines the disparity in prescription drug spending across countries. The Organisation for Economic Co-operation and Development (OECD) ranks the United States highest in average spending, at $1,218 per resident – over $200 more than...
May 30, 2025 | Announcements, Compliance, Consolidated Appropriations Act of 2021 (CAA), Pharmacy, Regulatory
As you’ll recall, the Consolidated Appropriations Act of 2021 (CAA) requires all health plans to file a pharmacy data report annually to the Centers for Medicare & Medicaid Services (CMS). Each year, the Prescription Drug Data Collection reporting (RxDC)...
May 5, 2025 | Legislative, News, Pharmacy, Pharmacy Benefits Manager (PBM), State legislation
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
